Working… Menu

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05005975
Recruitment Status : Recruiting
First Posted : August 16, 2021
Last Update Posted : October 8, 2021
Information provided by (Responsible Party):
Mitsubishi Tanabe Pharma Development America, Inc.

Brief Summary:
To evaluate the long-term safety and tolerability of oral dersimelagon.

Condition or disease Intervention/treatment Phase
EPP XLP Drug: MT-7117 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Actual Study Start Date : August 10, 2021
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : September 2023

Arm Intervention/treatment
Experimental: Dersimelagon 100mg Drug: MT-7117
Other Name: Dersimelagon

Primary Outcome Measures :
  1. Number of patients with Treatment emergent adverse events (TEAEs) (including serious adverse events [SAEs] and adverse events of special interest [AESIs]). [ Time Frame: up to a maximum 24 months ]
    Vital signs (blood pressure, respiratory rate, pulse rate, and body temperature), Clinical laboratory examinations (hematology, coagulation, biochemistry, urinalysis, and others), 12-lead electrocardiogram (ECG) parameters (Mean Heart Rate, PR Interval, QRS Duration, QT interval, QTcB and QTcF) will be assessed.

  2. Number of patients with abnormal Physical examination data [ Time Frame: up to a maximum 24 months ]
    Physical examination consists of assessment of abdominal, respiratory, cardiovascular, general appearance, and others.

  3. Number of patients with Nevi appearance [ Time Frame: up to a maximum 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1. Subjects provided written informed consent to participate. For adolescent subjects, both adolescent assent and parental consent will be provided.
  • 2. Subjects who complete MT-7117-G01 (complete through Week 58 [Visit 12])
  • 3. Subjects have a body weight of ≥30 kg.
  • 4. Subjects are willing and able to travel to the study sites for all scheduled visits.
  • 5. In the Investigator's opinion, subject can understand the nature of the study and any risks involved in participation, and is willing to cooperate and comply with the protocol restrictions and requirements (including travel).
  • 6. Female subjects who are non-lactating and have a negative urine pregnancy test at baseline visit prior to receiving the first dose of study drug.
  • 7. Female subjects of childbearing potential and male subjects with partner of childbearing potential must agree to use 2 effective methods of contraception including barrier method (especially for female subjects, one method must be highly effective method)

Exclusion Criteria:

A subject will NOT be eligible for this study if ANY of the following criteria apply:

  • 1. History or presence of photodermatoses other than EPP or XLP.
  • 2. Presence of clinically significant hepatobiliary disease at Screening.
  • 3. Subjects with AST, ALT, ALP ≥3.0 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN at Screening.
  • 4. Subjects with or having a history (in the last 2 years) of excessive alcohol intake in the opinion of the Investigator.
  • 5. History of melanoma.
  • 6. Presence of melanoma and/or lesions suspicious for melanoma at Screening.
  • 7. History of familial melanoma (defined as having 2 or more first-degree relatives, such as parents, sibling and/or child).
  • 8. Presence of squamous cell carcinoma, basal cell carcinoma, or other malignant skin lesions. Any suspicious lesions or nevi will be evaluated. If the suspicious lesion or nevi cannot be resolved through biopsy or excision, the subject will be excluded from the study.
  • 9. History or presence of psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation and/or safety of the subjects.
  • 10. Presence of clinically significant acute or chronic renal disease based upon the subject's medical records including hemodialysis; an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 as calculated by the CKD-EPI creatinine equation (2009) for adults and by the Schwartz creatinine equation for adolescents (2009). MDRD can be used for adults per local recommendations.
  • 11. Presence of any clinically significant disease or laboratory abnormality which, in the opinion of the Investigator, can interfere with the study objectives and/or safety of the subjects.
  • 12. Female subjects who are pregnant, lactating, or intending to become pregnant during the study.
  • 13. Treatment with phototherapy or afamelanotide within 3 months before baseline (Visit 2).
  • 14. Treatment with cimetidine or antioxidant agents at doses which, in the opinion of the Investigator, may affect study endpoints (including but not limited to beta-carotene, cysteine, pyridoxine) within 4 weeks before baseline (Visit 2).
  • 15. Chronic treatment with any scheduled analgesic agents including, but not limited to opioids and opioid derivatives such as morphine, hydrocodone, oxycodone, fentanyl, or their combination with other unscheduled analgesics or non-steroidal anti-inflammatory drug (Percocet and Vicodin-like prescription drugs) within 4 weeks before baseline (Visit 2). Acute use of scheduled narcotics greater than 3 months prior to baseline, over-the-counter medications (OTCs), such as non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin for analgesia, or prior temporary use of scheduled agents within 3 months of baseline (Visit 2) are not excluded.
  • 16. Treatment with any drugs or supplements which, in the opinion of the Investigator, can interfere with the objectives of the study or safety of the subjects.
  • 17. Previous treatment with any investigational agent other than dersimelagon within 12 weeks before Screening OR 5 half-lives of the investigational product (whichever is longer).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05005975

Layout table for location contacts
Contact: Clinical Trials Information Desk, To prevent mis-communication, please e-mail

Layout table for location information
United States, California
Marvel Clinical Research, LLC Not yet recruiting
Huntington Beach, California, United States, 92647
University of California at San Francisco-CSF Porphyria Center Not yet recruiting
San Francisco, California, United States, 94143
United States, Florida
University of Miami School of Medicne, Center for Liver Diseases Not yet recruiting
Miami, Florida, United States, 33136
United States, Massachusetts
MetroBoston Clinical Partners, LLC Recruiting
Brighton, Massachusetts, United States, 02135-3211
United States, Missouri
Kansas City Research Institute Not yet recruiting
Kansas City, Missouri, United States, 64131
United States, New York
Icahn School of Medicine at Mount Sinai (ISSMS)-The Mount Sinai Hospital (MSH) Not yet recruiting
New York, New York, United States, 10029
United States, North Carolina
Wake Forest University Baptist Health Not yet recruiting
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Remington-Davis Clinical Research Recruiting
Columbus, Ohio, United States, 43215
United States, Pennsylvania
Thomas Jefferson University Not yet recruiting
Philadelphia, Pennsylvania, United States, 19107
United States, Texas
The University of Texas Medical Branch (UTMB) Not yet recruiting
Galveston, Texas, United States, 77555
United States, Washington
University of Washington-Seattle Cancer Care Alliance Not yet recruiting
Seattle, Washington, United States, 98109
Canada, Alberta
University of Alberta Not yet recruiting
Edmonton, Alberta, Canada, T6G2V2
Westfaelische Wilhelms-Universitaet Muenster Not yet recruiting
Muenster, Northrhein Westalien, Germany, 48149
Charite - Universitaetsmedizin Berlin Not yet recruiting
Berlin, Germany, 10117
United Kingdom
University of Manchester Not yet recruiting
Salford, Manchester, United Kingdom, M6 8HD
Evelina London Children's Hospital - Guy's & St Thomas' NHS Foundation Trust Not yet recruiting
London, United Kingdom, SE1 9RT
Sponsors and Collaborators
Mitsubishi Tanabe Pharma Development America, Inc.
Layout table for investigator information
Study Director: Head of Medical Science Mitsubishi Tanabe Pharma Development America, Inc.
Layout table for additonal information
Responsible Party: Mitsubishi Tanabe Pharma Development America, Inc. Identifier: NCT05005975    
Other Study ID Numbers: MT-7117-A-301
First Posted: August 16, 2021    Key Record Dates
Last Update Posted: October 8, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Protoporphyria, Erythropoietic
Porphyrias, Hepatic
Liver Diseases
Digestive System Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Metabolic Diseases